FOR IMMEDIATE RELEASE

Mitralign Presents Percutaneous Treatment Options for Tricuspid Regurgitation Repair at ESC

European Society of Cardiology (ESC) Congress highlights need for transcatheter tricuspid valve treatment options

LONDON, ENGLAND and TEWKSBURY, MA – September 1, 2015 – Mitralign shared early experience with its Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) designed to treat tricuspid regurgitation (TR) in a September 1 symposium at the European Society of Cardiology (ESC) Congress in London this week. The company continues to raise awareness of emerging treatment options for TR based on outcomes reported from compassionate use cases utilizing its PTVAS.

"The heart failure community continues to see patients with tricuspid regurgitation and we have very limited treatment options after medical therapy," commented Stefan D. Anker, MD Professor of Innovative Clinical Trials, University Medicine, Göttingen Germany and co-chair of the a symposium. "The emergence of innovations such as the Mitralign PTVAS means we may soon have a percutaneous repair option for tricuspid regurgitation rather than traditional surgery."

The symposium "Tricuspid Regurgitation in the Heart Failure Population: How to Treat It" was co-chaired by Anker and Gerasimos Filippatos, MD, Athens, Greece and reviewed both surgical and transcatheter approaches for the treatment of TR. Prof. Dr. med. J. Schofer, Hamburg, Germany and Azeem Latib, MD, Milan, Italy presented case reviews and information on compassionate use cases using Mitralign's Percutaneous Tricuspid Valve Annuloplasty System (PTVAS).

"We have seen very encouraging results treating tricuspid regurgitation using our platform and, similar to our United States tricuspid IDE, we are planning to commence a European CE study in the coming months," stated Rick Geoffrion, chief executive officer of Mitralign.

Mitralign is the only company to provide physicians with the tools they need to perform minimally invasive, percutaneous procedures for both functional mitral regurgitation and tricuspid regurgitation. Both systems utilize the same innovative platform. The Mitralign Percutaneous Annuloplasty System (MPAS) is expected to receive CE mark approval for treatment of functional mitral regurgitation (FMR) in 2015. Currently, Mitralign's Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) and Percutaneous Annuloplasty System (MPAS) are under clinical investigation and not available for sale or distribution.

Additional information on both the PTVAS and the MPAS will be presented in 2015 at PCR London Valves, September 20-22 in Berlin and during TCT in San Francisco, October 11-15.

About Tricuspid Regurgitation (TR) Tricuspid regurgitation occurs when the tricuspid valve fails to open and close properly, causing blood to flow backwards into the right atrium. If left untreated, TR can lead to heart enlargement and heart failure. In the U.S. alone, there are an estimated 1.6 million patients suffering from TR.[1] It is estimated that 50% of patients with mitral regurgitation have moderate to severe tricuspid regurgitation.[2] TR is currently undertreated by surgery. In the U.S. surgeons treat only 5,500 patients per year, most of them in conjunction with left heart surgeries. When treating the valves, surgeons choose repair 90% of the time versus replacement (10%).[3]

About Mitralign Inc.
Mitralign Inc. is the valve repair company with the only direct transcatheter annuloplasty system designed to treat both functional mitral regurgitation and functional tricuspid regurgitation. The company is a venture-backed, medical innovation company located near Boston, Massachusetts, USA. For more information, visit www.mitralign.com.

1. Stuge O., Liddicoat J., et al. JTCS 2006;132:1258-61
2. Argarwal et al. Circ Cardiovasc Interv 2009;2:565-573
3. RogersJH.Circulation2009:119: 2718-25

# # #

Company Contact:
David Schleifer
Director of Marketing
Mitralign Inc.
+617.869.6166
dschleifer@mitralign.com